Funding Received
$7.4 Million in 2 Rounds from 2 Investors
Most Recent Funding
$5.7 Million Venture on December 18, 2012
Southport, CT
Thetis Pharmaceuticals develops novel prescription drugs for the treatment of diabetes, hypertriglyceridemia and dyslipidemia.

Detailed Description


Thetis Pharmaceuticals LLC is a bio-pharmaceutical company creating innovative chemistry and regulatory strategies in the development of prescription drugs in the Omega-3 arena.

The Company has three differentiated and IP-protected drug candidates at varying stages of development: TP-101 for the treatment of type 2 diabetes, TP-943 for the treatment of hypertriglyceridemia and mixed dyslipidemia, and TP-721 for the prevention and treatment of atrial fibrillation.

The key innovation underlying Thetis’ drug portfolio revolves around pharmaceuticalizing Omega-3 poly- unsaturated fatty acids into solid, water-soluble, new chemical entities (NCEs). This technology creates NCEs that instantaneously dissociate in aqueous media to deliver known entities in either a superior or targeted manner. Since the delivered entities are known drugs with excellent safety profiles, the Company expects to bypass many pre-clinical and clinical safety requirements and seek expedited registration in the U.S. Furthermore these novel chemical compounds have excellent prospects for superiority over existing Omega-3 drugs.

Funding Rounds (2) - $5.7M


Investors (2)

  • 1aa3ff9ff75842b011a909e1f518ae84

    Stonehenge Capital

    Stonehenge Capital Company is a national specialty finance company, with expertise in private...
  • 0a1fc8ca9464a6026e63bfd6586fdf01

    Connecticut Innovations

    Connecticut Innovations provides strategic capital and operational insight to to companies in...

Offices/Locations (1)

  • Office

    167 Old Post Road

    Southport, CT 06890